

February 13, 2025

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA**

**Sub: Outcome of Board Meeting held on Thursday, February 13, 2025**

**Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we Zota Health Care Limited (“the Company”) would like to inform you that the Board of Directors of the Company in its Meeting held on Thursday, February 13, 2025 at 02:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have *inter alia*, discussed and approved the following business:

1. Considered and approved standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (**Annexure –1**).

The unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at [www.nseindia.com](http://www.nseindia.com) and on Company’s website at [www.zotahealthcare.com](http://www.zotahealthcare.com)

The Board meeting concluded at 7:15 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat  
Encl: a/a

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors of  
**Zota Health Care Limited**

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") for the quarter and nine months ended **December 31, 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

### **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

### **Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

# PRADEEP K SINGHI & ASSOCIATES

## CHARTERED ACCOUNTANTS

---

Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pradeep K. Singhi & Associates**  
**Chartered Accountants**  
**FRN : 0126027W**

**Date: 13/02/2025**

**Place: Surat**

**Pradeep Kumar Singhi**  
**(Partner)**  
**UDIN: 25024612BMONHY3287**

Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2024

(Amount ₹ in Lakhs, except per share data)

Particulars	Quarter Ended			Nine months ended		Year Ended
	31-12-2024 (Unaudited)	30-09-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	31-03-2024 (Audited)
I. Revenue from Operations	6813.08	5900.92	4283.46	17934.36	11923.54	16658.50
II. Other Income	168.91	97.01	37.76	312.81	135.81	205.19
III. <b>Total Income</b>	<b>6981.99</b>	<b>5997.93</b>	<b>4321.22</b>	<b>18247.17</b>	<b>12059.35</b>	<b>16863.69</b>
IV. <b>Expenses:</b>						
Cost of Materials Consumed	303.90	430.72	400.53	1013.73	983.71	1277.46
Purchases of Stock-in-Trade	4699.98	2907.89	2355.30	9952.55	5954.96	9520.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(943.99)	215.20	(41.09)	(168.56)	701.98	(352.67)
Employee Benefit Expenses	854.97	729.09	528.42	2228.23	1384.24	1997.36
Finance Costs	3.83	51.91	0.43	97.66	30.05	36.47
Depreciation / Amortisation and Depletion Expense	81.75	73.35	83.11	222.74	214.87	300.73
Other Expenses	1767.41	1293.73	827.58	4158.43	2314.55	3593.37
<b>Total Expenses</b>	<b>6767.84</b>	<b>5701.91</b>	<b>4154.27</b>	<b>17504.78</b>	<b>11584.36</b>	<b>16373.07</b>
V. Profit before Exceptional items and tax from continuing operations (III-IV)	214.15	296.02	166.94	742.38	474.99	490.61
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	214.15	296.02	166.94	742.38	474.99	490.61
VIII. Tax Expense:						
(1) Current tax	(15.23)	84.74	50.59	134.22	139.05	153.08
(1.1) I.T. & DD Tax Provision Created Short/ excess	(2.49)	-	(6.28)	(2.49)	(6.28)	(6.28)
(2) Deferred Tax	(24.10)	23.91	(6.94)	(9.26)	(26.56)	(5.82)
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	207.77	235.19	115.68	601.39	315.66	337.99
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	207.77	235.19	115.68	601.39	315.66	337.99
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	22.94	(20.58)	(10.31)	12.98	15.93	19.82
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(5.77)	5.18	2.59	(3.27)	(4.01)	(4.99)
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
Other comprehensive income for the period, net of tax	17.17	(15.40)	(7.71)	9.71	11.92	14.83
<b>Total comprehensive income for the period (XIII + XIV)</b>	<b>224.94</b>	<b>219.79</b>	<b>107.97</b>	<b>611.10</b>	<b>327.59</b>	<b>352.82</b>
Paid-up Equity Share Capital	2757.10	2740.76	2584.73	2757.10	2584.73	2584.73
Other Equity	-	-	-	-	-	9592.80
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.76	0.89	0.45	2.23	1.23	1.32
(2) Diluted (in ₹)	0.70	0.82	0.44	2.07	1.21	1.29

\* denotes figures less than a lakh

For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
Company Secretary  
Ashvin Variya  
Date: 13-02-2025  
Place : Surat

  
Chief Financial Officer  
Viral Mandviwala



For Pradeep K. Singhi & Associates  
Chartered Accountants  
Firm No. 0126027W

Pradeep Kumar Singhi  
(Partner)  
M. No. 200/024612

**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com  
CIN : L24231GJ2000PLC038352

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors of  
**Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and nine months ended December 31, 2024** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

### **Management's Responsibility**

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

### **Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt.) Ltd. (Wholly Owned Subsidiary)

# PRADEEP K SINGHI & ASSOCIATES

## CHARTERED ACCOUNTANTS

---

- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- d. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- e. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- f. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

### Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

### Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total revenues of Rs. 3367.82 Lakhs and Rs.7951.52 Lakhs, total net profit/(loss) after tax of Rs. (1896.76) Lakhs and Rs. (4593.72) Lakhs and total comprehensive income of Rs. (1887.83) Lakhs and Rs. (4585.21) Lakhs, respectively for the quarter and nine months ended December 31, 2024, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

**For Pradeep K. Singhi & Associates**  
**Chartered Accountants**  
**FRN : 0126027W**

**Date: 13/02/2025**

**Place: Surat**

**Pradeep Kumar Singhi**  
**(Partner)**  
**UDIN: 25024612BMONHZ7791**

Particulars	Quarter Ended			Nine months ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	7212.38	6727.58	4693.14	19570.03	13085.28	18048.85
II. Other Income	50.59	54.27	15.14	106.65	69.93	115.61
III. Total Income	7262.97	6781.86	4708.28	19676.68	13155.21	18164.46
IV. Expenses:						
Cost of Materials Consumed	303.90	430.72	400.53	1013.73	983.71	1277.46
Purchases of Stock-in-Trade	4808.81	2905.91	2355.30	10036.34	5954.96	9520.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1929.48)	(211.11)	(218.55)	(2107.23)	452.27	(1127.79)
Employee Benefit Expenses	2381.99	2006.36	775.77	6012.99	1833.67	3045.05
Finance Costs	157.40	285.33	113.87	732.54	310.72	478.82
Depreciation / Amortisation and Depletion Expense	1134.53	951.23	507.92	2888.11	1328.63	2008.51
Other Expenses	2254.22	1682.72	1046.78	5434.14	2956.74	4578.35
Total Expenses	9111.37	8051.15	4981.63	24010.62	13820.70	19780.75
V. Profit before Exceptional items and tax from continuing operations (III-IV)	(1848.40)	(1269.30)	(273.35)	(4333.94)	(665.49)	(1616.29)
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	(1848.40)	(1269.30)	(273.35)	(4333.94)	(665.49)	(1616.29)
VIII. Tax Expense:						
(1) Current tax	(15.23)	84.74	50.59	134.22	139.05	153.08
(1.1) I.T. & DD Tax Provision Created Short/ excess	(2.49)	-	(6.28)	(2.49)	(6.28)	(6.28)
(2) Deferred Tax	(63.86)	135.94	23.83	80.65	55.24	328.31
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1894.54)	(1218.10)	(293.84)	(4385.02)	(743.02)	(1434.79)
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	(1894.54)	(1218.10)	(293.84)	(4385.02)	(743.02)	(1434.79)
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	34.81	(22.78)	(10.64)	24.41	16.51	24.59
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(8.74)	5.73	2.68	(6.13)	(4.15)	(6.18)
B (i) Items that will be reclassified to Statement of profit and loss	0.03	(0.01)	*	(0.04)	(0.03)	(0.07)
(ii) Income Tax relating to items that will be reclassified to profit and loss	*	*	*	*	*	0.02
Other comprehensive income for the period, net of tax	26.09	(17.06)	(7.97)	18.26	12.33	18.36
Total comprehensive income for the period (XIII + XIV)	(1868.45)	(1235.16)	(301.80)	(4366.77)	(730.69)	(1416.42)
Profit attributable to:						
Owners of the parent	(1868.17)	(1210.24)	(293.84)	(4350.80)	(743.02)	(1434.79)
Non-controlling interest	(26.37)	(7.86)	-	(34.23)	-	-
Other comprehensive income attributable to:						
Owners of the parent	26.09	(17.06)	(7.97)	18.26	12.33	18.36
Non-controlling interest	-	-	-	-	-	-
Total Comprehensive Income attributable to:						
Owners of the parent	(1842.08)	(1227.30)	(301.80)	(4332.54)	(730.69)	(1416.42)
Non-controlling interest	(26.37)	(7.86)	-	(34.23)	-	-
Paid-up Equity Share Capital	2757.10	2740.76	2584.73	2757.10	2584.73	2584.73
Other Equity						6412.92
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	(6.80)	(4.57)	(1.14)	(16.12)	(2.90)	(5.59)
(2) Diluted (in ₹)	(6.31)	(4.23)	(1.11)	(14.96)	(2.84)	(5.47)

\* denotes figures less than a lakh  
For and on behalf of the Board

  
(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)

  
Company Secretary  
Ashvin Variya  
Date: 13-02-2025  
Place : Surat

  
Chief Financial Officer  
Viral Mandviwala



For Pradeep K. Singhi & Associates  
Chartered Accountants  
Firm No. 0126027W

Pradeep Kumar Singhi  
(Partner)  
M. No. 200/024612

**Registered Office :**

Zota House, 2/396, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com  
CIN : L24231GJ2000PLCO38352

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122

**Notes:**

1. The above financial results for the quarter and nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 13, 2025.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2024.
4. During the quarter; upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has on December 04, 2024 allotted 1,63,425 equity shares upon conversion of warrants to 17 Warrant Holders.
5. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
6. The consolidated results include the result of following companies:
  - A) Wholly owned subsidiaries:
    - i) Zota Healthcare Lanka (Pvt) Ltd
    - ii) Davaindia Health Mart Limited
    - iii) Zota Nex Tech Limited
  - B) Subsidiaries:
    - i) Everyday Herbal Beauty Care Private Limited
    - ii) Everyday Herbal Beauty And Wellness Care Private Limited
7. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 10503.66 lakhs and a corresponding Lease Liability of Rs. 11530.73 lakhs as at December 31, 2024. The impact of this on the consolidated profit for the quarter and nine months ended December 31, 2024 is Rs. 138.77 lakhs and Rs. 453.69 lakhs respectively.
8. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.



**Registered Office :**

Zota House, 2/396, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com  
CIN : L24231GJ2000PLCO38352

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122